Companies: 10,795·Total market cap: $144.5T
Quest Diagnostics Incorporated

Quest Diagnostics Incorporated

DGXNYSEHealthcare● Active
$200.29
+$4.17(+2.13%)
Market Cap$22.2B
P/E Ratio
52W High$213.5
52W Low$164.65

Quest Diagnostics Incorporated (DGX) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

dgx · stock forecast · 34 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 34 Wall Street analysts in the past 3 months

SellBuy

Hold

34 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
13
Hold
18
Sell
3
Strong Sell
0
Total: 34 · Buy rate: 38.2%

12-Month Price Target

High

$235

Consensus

$221

+10.1% upside

Low

$210

Median: $220 · Last Close: $200.29

The Quest Diagnostics Incorporated (DGX) analyst consensus is Hold, based on ratings from 34 Wall Street analysts over the past 3 months. The average 12-month DGX price target is $220.57, representing +10.1% upside from the current price of $200.29.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $221 (10.1%)

Consensus Target

$220.57

10.1% upside

High Target

$235

17.3%

Low Target

$210

4.8%

Current Price

$200.29

as of today

Based on analyst price targets, the DGX stock price prediction for the next 12 months ranges from $210 to $235. The consensus DGX price forecast of $220.57 implies 10.1% upside from the current price of $200.29.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$201.580.64%

1-day model range: $201.12–$202.04. Peak: $202.04 (+0.64%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$222+10.9%
2028$238+18.7%
2029$249+24.2%
2030$256+27.9%
2031+30.4%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BULLISH

Based on 14 technical indicators

93%0%7%
13Buy
0Neutral
1Sell
RSI (14)76.0Overbought
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · DGX · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$195.09BUY
MA 10$194.86BUY
MA 20$192.46BUY
MA 50$194.24BUY
MA 100$195.43BUY
MA 200$188.67BUY
Current $DGX · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$196.38BUY
EMA 10$194.98BUY
EMA 20$193.95BUY
EMA 50$194.05BUY
EMA 100$192.94BUY
EMA 200$188.27BUY
Current $DGX · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
UBS2026-04-22
Maintains
NeutralNeutral
Truist Securities2026-04-22
Maintains
HoldHold
Barclays2026-04-22
Maintains
OverweightOverweight
Baird2026-04-22
Maintains
NeutralNeutral
Evercore ISI Group2026-04-08
Maintains
In LineIn Line
Mizuho2026-02-12
Maintains
OutperformOutperform
Evercore ISI Group2026-02-11
Maintains
In LineIn Line
Jefferies2026-02-11
Maintains
BuyBuy
Truist Securities2026-02-11
Maintains
HoldHold
UBS2026-02-11
Maintains
NeutralNeutral

Wall Street analysts have recently issued updated ratings on Quest Diagnostics Incorporated (DGX) stock. Of the recent 259 rating actions, 45 were upgrades and 30 were downgrades. 34 analysts currently cover DGX.

Analyst Recommendation Trends

Buy ratings01↑ +1
Hold ratings14↑ +3
Sell ratings00

DGX analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$11.9B

↓ 8.3% YoY

Revenue Next Year

$12.4B

↑ 4.5% YoY

EPS This Year

$10.75

EPS Next Year

$11.67

↑ 8.6% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast DGX EPS of $10.75 for the current fiscal year, based on estimates from 12 analysts. The DGX revenue forecast is $11.9B for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The DGX stock forecast is supported by two independent data sources: analyst consensus ratings from 34 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus DGX price target is $220.57 (+10.1% upside), with an analyst consensus of Hold.

The DGX short-term stock prediction for tomorrow is $201.58 (+0.64%). The DGX stock price prediction for 2027 estimates an average of $222. The DGX stock prediction for 2030 projects a range of $250–$263.

Quest Diagnostics Incorporated trades on NYSE under the ticker DGX. The DGX stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 38% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

DGX forecast · 8 questions

According to 34 Wall Street analysts, the average 12-month DGX price target is $220.57, with a high forecast of $235.00 and a low of $210.00. The median price target is shown in the chart above when available. This implies +10.1% potential upside from the current price of $200.29.

DGX price targetWhat is DGX price targetDGX analyst price targetDGX 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.